CureVac BV CVAC shares are trading lower after the company and Bayer reportedly terminated their vaccine manufacturing partnership.
More news came around 1:20 pm EDT after an SEC filing showed that dievini Hopp BioTech holding, which holds roughly 42% of outstanding CureVac shares, plans to sell some of its shares.
CureVac NV is a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid. The company's product portfolio includes clinical and pre-clinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy.
CureVac has a 52-week high of $151.80 and a 52-week low of $37.54.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
